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Efficacy of an infant formula containing 
anti-IZscherichia coli colostral antibodies from 
hyperimmunized cows in preventing diarrhea in 
infants and children: a field trial 
Haifa Ibrahim Tawfeek,(l) Najim Hadi Najim@) and Shalan Al-Mashikhic3) 
Objective: To examine the efficacy of using oral bovine hyperimmune immunoglobulin concentrate with high-titer 
antibodies against Escherichia coli in preventing diarrhea caused by enteropathogenic E. coli. 
Design and setting: This was a randomized, double-blind, controlled field trial conducted at the Al-Sheikh Omer 
Maternal and Child Health Center in Baghdad, Iraq from May to September 1998. 
Participants: One hundred and twenty-five infants who satisfied the study criteria were included. One hundred and 
seven infants had adequate outcome data for the assessment of efficacy. 
Intervention: Infants were randomly assigned to receive either immunoglobulin concentrate-supplemented infant 
formula or non-supplemented control formula for 7 days. Groups were matched for physical characteristics at 
enrollment in the study. Another group, which was breastfed, was included to allow the collection of diarrhea 
morbidity data. Anthropometrics and diarrhea1 morbidity data were collected by weekly monitoring during the 6- 
month follow-up period. 
Results: The infants receiving supplemented formula had a lower incidence of diarrhea than the infants receiving 
control formula (PcO.05). Episodes of diarrhea were shorter in infants receiving supplemented formula (PcO.01). 
Moreover, infants receiving supplemented formula gained significantly more weight than control infants after 
8 months of follow-up. The preparation was safe and well tolerated. 
Conclusion: The results indicate that the reduction in morbidity associated with formula supplementation is of 
sufficient magnitude to be of public health significance. The use of these preparations provides an effective method 
for the prevention of diarrhea1 diseases. 
Int J Infect Dis 2003; 7: 120-128 
INTRODUCTION 
Diarrhea morbidity and mortality rates are high among 
infants and young children in developing countries. This 
is also true in Iraq. 1-4 Recently, Tawfeek et al5 reported 
in a retrospective study that 28.63% of deaths in infants 
and children admitted to pediatric hospitals in Baghdad 
were associated with diarrhea. 
Prevention of diarrhea should result in improved 
survival and healthier children in general. However, 
one of the major problems with diarrhea1 disease is its 
prevention.6 Treatment or prophylaxis with antibiotics 
is a possibility in the case of bacterial diarrhea,7 but the 
pattern of high rates of resistance to antibiotics requires 
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a major commitment and adequate resources. Active 
immunization offers one approach to this problem, but 
the development of vaccines has been s10w.~ Alter- 
natively, passive immunity may be provided either by 
breastfeeding or by artificial feeding of antibody- 
containing preparations. Repeated attempts have been 
made to counteract diarrhea by the oral administration of 
bovine immunoglobulins,9-13 but the use of this type of 
intervention for preventative or therapeutic purposes 
in infants has not been reported in Iraq. Therefore, we 
conducted a randomized, controlled trial to evaluate the 
efficacy of an infant milk formula containing bovine milk 
immunoglobulin concentrate with specific activity against 
enteropathogenic Escherichia coli (EPEC) in a cohort of 
healthy infants in a field trial in preventing diarrhea. 
METHODS 
Study sites 
The study was conducted at Al-Sheikh Omer Maternal 
and Child Health Center, Baghdad, Iraq.The Committee 
of Medical Research at the Ministry of Health and the 
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Medical Committee at the Al-Sheikh Omer Maternal 
and Child Health Center, Baghdad approved the study 
protocol. Informed parental consent was obtained for all 
eligible infants enrolled in the study. 
Study population 
Mothers were informed about the study by means of 
posters, leaflets and personal interview in the parti- 
cipating center prior to the selection of infants. Infants 
and young children born between May 1997 and 
February 1998 living in the Al-Sheikh Omer area were 
selected. All mother-infant pairs satisfying the selection 
criteria were asked to participate, and there were no 
refusals. All mothers were informed of the general 
objectives of the project. Reasonable efforts were made 
to promote exclusive breastfeeding. Diarrhea was not 
emphasized, in order to avoid biased answers on the part 
of mothers during the study. 
One hundred and twenty-five infants and young 
children fulfilled the criteria for inclusion in the study. 
The recruitment of 125 subjects allowed for losses due 
to incorrect addresses, refusals, and families moving 
away from the area during the study. Infants were 
eligible for inclusion in the trial if they were apparently 
healthy, their birth weight was 22.5 kg, they were non- 
breastfed (fed with formula or formula plus weaning 
foods), they were aged between 3 and 6 months, and 
their nutritional status was within normal limits14 (length- 
for-age, length-for-weight, and weight-for-age Z-scores 
were between -2 SD and +2 SD Z-scores). 
To ensure that the infants satisfied the inclusion 
criteria, study applicants underwent a detailed physical 
and medical examination by pediatricians. Infants were 
excluded if, at enrollment, they had a history of allergy 
to cow’s milk or they were receiving lactose-free, protein 
hydrolysate formula for a malabsorption disorder. They 
were also excluded from the study if they were diag- 
nosed with a chronic disease, they were hospitalized, or 
they had received antibiotic medication for any reason 
for >2 weeks. 
A questionnaire was used to collect the following 
information: maternal characteristics (age, educational 
level, and family income), weight at birth, date of birth, 
and illness of infant during the preceding week, including 
a day-by-day record of the occurrence of diarrhea and 
its severity. 
Study design 
This was a double-blind, randomized, controlled trial 
conducted during the diarrhea season from May to 
September 1998. Infants were randomly assigned to 
receive either one of three supplemented formulas (treat- 
ment groups) or a standard formula (control group) for 
1 week. The investigators allotted the infants fulfilling 
the inclusion criteria alternately to the study groups until 
the final number of 125 infants was reached. Mothers 
were provided, without charge, with a 7-day supply of 
study formula. The use of milk and milk products other 
than the study formula was discouraged. 
In order to maintain blinding, the formula box was 
assigned with a letter code. The letter code was unknown 
to the mothers, the investigators and the sponsor 
personnel directly involved in monitoring the study (e.g. 
nurses) until the data were analyzed. The letter code for 
a particular infant was only to be broken in the event of 
a serious adverse event. The blinding was maintained 
throughout the study. All formulas were identical in 
appearance and taste. 
The study formula (Bilady) was prepared and sup- 
plied in powdered form by Baby Milk Plant, Baghdad, 
Iraq. The standard (control) formula contained casein- 
based solids, lactose, and vitamins. The treatment formula 
consisted of the standard formula plus additional E. coli- 
specific or normal colostral immunoglobulin concentrate. 
Infants to receive treatment were randomized to 
one of three treatment groups or the control group: 
Treatment group A-O.5 g/kg body weight per day of 
hyperimmune bovine immunoglobulin concentrate 
(polyvalent: 055:K59; Olll:K58; 0125:K70; 0126:K71; 
0128:K67). 
Treatment group B-O.5 g/kg body weight per day of 
hyperimmune bovine immunoglobulin concentrate 
(monovalent: 0126:K71). 
Treatment group C-O.5 g/kg body weight per day 
of normal bovine immunoglobulin concentrate from 
non-immunized cows (normal). 
The infants in the control group received the same basic 
milk formula without immunoglobulin concentrate 
supplementation. A fifth group of breastfed infants was 
also included in the study. These infants were followed 
up only for cases of diarrhea. Infants were followed up 
at weekly intervals for 6 months. 
Anthropometry 
The study included determination of age, weight, and 
length. Age was calculated to the nearest month, using 
the date of birth obtained from the birth certificate and 
the date of examination. The anthropometrics measure- 
ments were conducted as described by the United 
Nations.15 The weights of infants were measured with 
metric beam scales, calibrated daily, and recorded to the 
nearest 100 mg while the infants were wearing shorts 
and sleeveless shirts. Length was measured to the 
nearest 0.1 cm on a recumbent board. Infant weight was 
measured weekly, while length was measured at enroll- 
ment and at the end of the study. Weight-for-age (WA), 
length-for-age (LA) and weight-for-length (WL) Z-scores 
were calculated using NCHS reference data.14 
Clinical monitoring 
In addition to the investigators, two registered nurses 
especially trained for the study were in charge of the 
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fieldwork. This consisted of weekly visits to each house- 
hold involved in the study. During each visit, the investi- 
gators and nurses monitored the intake of milk, and 
asked about the general health of and the incidence of 
diarrhea in the infant. 
If, at the time of the weekly follow-up visit, a child 
had diarrhea, a form was completed, on which was 
recorded the start date of the diarrhea1 episode, the 
symptoms, and the treatment. The child was then 
referred to the health center for a medical check-up. 
The nurse recorded the exact amount of stools passed 
during each episode. The nurse repeated her visits to the 
family in the following days to complete the monitoring. 
The duration of the diarrhea1 episode was also reported. 
Diarrhea was recorded as any change in consistency 
(loose stools for 24 h or more), or an increase in the 
frequency of the stools by at least two distinct bowel 
motions compared to the habit for that infant. The 
mother’s own knowledge of the child was also taken into 
account in assessing stool frequency. A new episode was 
defined as one that was separated from the preceding 
one by a symptom-free interval of 23 days. Hospital- 
ization of infants with diarrhea was used as an indicator 
of the severity of the episode. A pediatrician determined 
the need for hospitalization during each episode. 
Milk immunoglobulin concentrate preparation 
Bovine colostrum from local breed cows at the College 
of Veterinary Medicine, University of Baghdad, or from 
private livestock farms, was used for this study. The 
technique used for preparation of E. coli antigens was 
as described by Hilpert et a1.i6 Groups of cows were 
immunized during the last 2 months prepartum. Either 
monovalent vaccine consisting of killed E. coli 0126:K71, 
or polyvalent vaccine representing five strains (055:K59, 
Olll:K58,0125:K70,0126:K71, and 0128:K67), was used 
for hyperimmunization. Isolation of colostral whey 
proteins (CWPs) was based on the method of Al- 
Mashikhi and Nakai.17 Colostrum from the first 6 or 
7 days after calving was immediately frozen and kept at 
-20°C until further treatment. The colostrum samples 
were defatted at 4000g at 4°C for 30 min. The samples 
were pasteurized at 62.5”C for 30 min. Casein was 
precipitated by milk renneting with commercially 
available rennin or by adjusting the pH to 4.6 with 1 M 
HCl, and then removing the precipitated casein by 
centrifugation at 10 OOOg for 15 min at 4°C. The bulk of 
the lactose and mineral salts was removed by exhaustive 
dialysis. The prepared CWP was concentrated, sterilized, 
and lyophilized. 
Immunoglobulins were isolated from colostrum 
using Sephadex G-200. The column of Sephadex G-200 
was equilibrated with 0.1 M Tris-HCl buffer, pH 8.0, 
containing 0.5 M NaCl. Sodium dodecylsulfate-poly- 
acrylamide gel electrophoresis was carried out in a 
vertical slab unit (LKB, Sweden), according to the 
method of Laemmli.ls Immunoelectrophoresis was 
carried out using 1% agarose in Tris-barbiturate buffer 
(pH 8.6). Agglutination tests were done in a microtiter 
system using polysterol plates with U-shaped wells.16 
Immunoglobulins from non-immunized cows were 
isolated in the same way. The antimicrobial activity of 
the milk immunoglobulin concentrate against the study 
EPEC serotypes was determined as described by Hilpert 
et a1.16 The antibody activity of the milk formula against 
EPEC was measured by an in vivo mouse protection 
test.16 
Laboratory methods 
Stool specimens were collected daily, whenever possible, 
during an episode of acute diarrhea and cultured for E. 
coli in MacConkey agar within 24 h of sample collection. 
EPEC was identified by screening 10 colonies from each 
culture by agglutination with antisera (Serum test Coli 
Anti-OK, Behringwerke AG, Germany) to classic EPEC 
serotypes. 
Immunoelectrophoresis 
Sterile phosphate-buffered saline (0.15 M, pH 7.4) was 
added to each stool sample. The suspension was shaken 
for 20 min at room temperature, cooled to 0°C and 
centrifuged at the same temperature at 35OOg for 15 min. 
Glass plates (85x95 mm) were coated with 12 mL of 
agarose in Tris-barbiturate buffer (pH 8.6). Electro- 
phoretic separation was carried out as described by 
Hilpert et a1,16 using 50 mL/well rabbit anti-bovine CWP 
(Miles Laboratories, Elkhart, IN, USA). 
Data analysis 
A two-tailed t-test was used to compare the groups. 
During the follow-up period, the duration of diarrhea 
was measured to the nearest hour to two endpoints: last 
liquid stool, and last unformed stool (semisolid or soft). 
The number of episodes, the duration of each episode 
and the number of stools per day were compared 
between the two groups using the Wilcoxon test. The 
cumulative incidence of diarrhea in infants receiving 
control and supplemented formula was calculated. 
Data entry was conducted using a personal 
computer. Weight and length information were con- 
verted to WA, LA and WL Z-score values, based on 
the standards of the National Center for Health 
Statistic/Centers for Disease Control (CDC)/World 
Health Organization by using ANTHRO Software.” 
Weight reduction per episode of diarrhea was calculated 
as: body weight on the first day of the episode minus 
body weight on the last day of the episode. Weight 
reduction per day of diarrhea (g/day) was calculated as: 
body weight on the first day of diarrhea minus body 
weight on the last day of diarrhea, divided by the 
number of days with diarrhea (duration). 
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RESULTS 
Subject enrollment 
In total, 217 participants were recruited. The disposition 
of the participants in the trial is shown in Figure 1. Of 
the 217 infants enrolled in the study, 125 were allocated 
to one of the four regimens as follows: 34 in treatment 
group A, 31 in treatment group B, 30 in treatment group 
C, and 30 in the control group. Ninety-two mothers 
were recruited into the breastfed group. At enrollment, 
infants in the treatment and control formula groups 
were well matched with regard to baseline pre- 
intervention characteristics (Table 1). 
Blinding was broken only for one infant in treat- 
ment group C, due to hospital admission. 
Diarrhea morbidity 
By contrast, there was no significant difference 
in any of the measured parameters between either of 
the other two treatment formula groups (B and C) and 
the control formula group (P>O.O5). A comparison of 
treatment group A with the breastfed group showed that 
there was no significant difference in the mean number 
of diarrhea1 episodes reported during the 6-month 
follow-up period between the groups (group A 1.9 
(SD 1.1) versus breastfed group 2.0 (SD 1.3), P>O.O5) 
(Table 2). 
Significantly fewer infants receiving supplemented Figure 2 shows that the cumulative incidence of 
formula (treatment group A) than receiving control diarrhea was significantly (P<O.OOl) reduced in infants 
formula developed acute diarrhea1 illness during their receiving the supplemented formula (group A). After 
6-month follow-up period (Table 2). In treatment group 6 months of follow-up, ~30% of the infants in group 
A, there was a mean of 1.9 (SD 1.1) diarrhea1 episodes A had never experienced an episode of such illness, 
per infant, which was significantly lower than the whereas 98% of the infants receiving the control 
Table 1. Subject characteristics 
3.5 (SD 2.6) episodes per infant reported in the control 
group (P<O.Ol). The severity of diarrhea, as judged by 
duration, was 4.5 (SD 3.6) days in treatment group A, 
compared with 6.5 (SD 4.3) days in the control group. 
The difference between the groups was statistically 
significant (PcO.01). The severity of diarrhea, measured 
by the number of stools per day, was also significantly 
different between the groups (Table 2). No infant in any 
group required hospitalization due to diarrhea. 
Supplemented treatment groups 
Variables 
Group A 
(n =30) 
Group 6 
(n=25) 
Group C 
(n=23) 
Control group 
(n=29) 
Birth weight (9)” 
Gender (female/male)a 
Length-for-age (SD score)a 
Weight-for-length (SD score)a 
Weight-for-age (SD score)a 
Mother’s age (year@ 
<20 
20-30 
>30 
Mother’s education (years)” 
Nil 
l-3 
4-6 
>7 
Family income (ID)b 
<10000 
10000-15000 
>I5000 
32512536 32562540 326Ok520 32Olk513 
15:15 12:13 13:lO 14:15 
-0.91 kO.08 -0.89kO.09 -0.9kO.21 -0.89kO.12 
-1.26-cO.07 -1.3-r-0.09 -1.31a0.07 -1.34kO.19 
-1.75kO.2 -1.69r0.8 -1.69r0.8 - 1.6520.98 
6 5 4 4 
14 13 11 12 
10 7 8 13 
6 5 4 8 
12 10 9 12 
9 8 7 5 
3 2 3 4 
10 10 8 12 
15 11 11 13 
5 4 4 4 
aMean, SD. 
blD, Iraqi Diner. 
Table 2. Diarrhea1 morbidity” 
Supplemented treatment groups 
Variables 
Group A 
(n=30) 
Group B 
(n=25) 
Group C 
(n=23) 
Control 
group 
(n =29) 
Breastfed 
group 
(n&3) 
No. of episodes 
Duration of episodes (days) 
No. of stools per day 
1.921.1 3.222.3 NS 3.6-t-1.9 NS 3.522.6 2.01t1.3 
4.5k3.6 5.321.4 NS 6.424.3 NS 6.5k4.3 4.620.9 
3.3k1.3 6.7-cl.5 NS 6.9k1.2 NS 6.6k1.4 3.1-1-0.9 
aValues are means. NS, not significant. P~0.05. 
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formula had at least one episode of diarrhea during the treatment formula (14 cultures for group A, 15 cultures 
same follow-up period. for group B, and 13 cultures for group C). The isolation 
In total, 56 stool cultures were collected, 14 cultures of E. coli was positive in two, six, seven and seven stool 
from the control group and 42 from infants receiving cultures for treatment groups A, B and C and the control 
Figure 1. The disposition of the participants in the trial. 
1.0. 
0.8. 
0.6. 
0.2. 
O- 
A 
0 
// 63 completed trial I/ 
Group A - Group C _._.- 
Group B ------ Control - 
I 
I I I I I I b 
1 2 3 4 5 6 
Months 
Figure 2. Cumulative incidence of diarrhea in infants receiving supplemented formula (treatment groups A, B and C) or control 
formula. 
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group respectively. The presence of intact bovine milk 
immunoglobulins was shown as a line of precipitation in 
the immunoelectrophoresis examination of stool extract 
of treatment group A only. No such line of precipitation 
in other groups was found. 
Nutritional indicators 
The mean changes in the WA, LA and WL Z-scores over 
the observation period are shown in Table 3. The 
increments in WA, LA and WL SD scores were 
significantly greater in treatment group A than in the 
control group (P<O.OOl). The treatment formula also 
ameliorated the weight reduction per day of diarrhea 
(21.3k12.0 g/day versus 45.9-+X9 g/day, PcO.05) (Table 
3) and per episode of diarrhea (95.8217.3 g versus 
298.4k29.4, PcO.05). By contrast, there were no signi- 
ficant differences in WA, LA or WL Z-score, weight 
reduction per day of diarrhea, and weight reduction per 
episode of diarrhea between either of the treatment 
groups B or C and the control group (P>O.O5). 
DISCUSSION 
Immunization is compulsory in Iraq, and therefore the 
infants recruited at any health center can be considered 
to be representative of the study base. Diarrhea mis- 
diagnoses based on maternal observations are probably 
unusual, because pre-established definitions of illness 
were given to all mothers at the time of enrollment into 
the study. 
In addition, mothers were blinded to the treatment 
category or the amount of bovine milk immunoglobulin 
supplementation. Participant mothers were instructed 
and supervised personally at each visit to detect any 
deviation from the treatment protocol, such as ingestion 
of milk formula by another child in the family, or 
distribution of milk formula to other members of the 
family. The mean birth weight and the nutritional 
indicators were similar among the study groups, so any 
difference in the morbidity rates cannot be attributed 
to a nutritionally immune response of the children.20 
Thus it is unlikely that differences in treatment out- 
comes were due to observer bias. It appears likely, there- 
fore, that supplementation with hyperimmune bovine 
Table 3. Nutritional indicator outcomesa 
immunoglobulin alone accounts for the observed 
differences among the study groups. 
A previous study performed in hospitalized infants 
demonstrated that the therapeutic use of bovine hyper- 
immune immunoglobulin in supplemented formula or 
diet during the acute phase of diarrhea caused by E. coli 
reduced the duration of diarrhea.13 In this study, we 
demonstrated that the oral administration of these 
immunoglobulins offered an attractive means of passive 
immunotherapy or prophylaxis against infant diarrhea 
due to EPEC. Early infancy is considered to be a period 
of special vulnerability to infectious diseases, because of 
the time lapse between the decline of acquired maternal 
immunity and the start of active immunoglobulin syn- 
thesis?O 
The efficacy of supplemented milk formula in 
reducing the incidence of diarrhea may be increased by 
extending coverage to include all the EPEC stereotypes 
that are believed to cause infantile diarrhea in Iraqi 
children.21 Moreover, feeding this type of formula can 
mitigate the severity of the diarrhea: those infants who 
received polyvalent supplemented formula (group A) 
and who developed diarrhea had fewer liquid stools for 
significantly less time than those who received the 
control formula (Table 2). The reduction in duration of 
diarrhea in children receiving supplemented formula 
(group A) might b e d ue to an enhancement of E. coli 
shedding, or more probably binding by the colostral 
antibody in the gut lumen. 
Overall, infants receiving supplementation with 
0.5 g/kg per day hyperimmune bovine immunoglobulin 
concentrate (group A) experienced a significant 
reduction in the number of diarrhea episodes, their 
frequency, and their duration. By contrast, there was no 
apparent benefit from the administration of monovalent 
bovine immunoglobulin directed against E. coli 0126:K71 
(group B). Recently Hassan et al*l showed that E. coli 
0126:K71 is less prevalent than other somatic and 
capsular antigenic E. coli strains associated with infantile 
diarrhea. This may be an explanation for the negative 
results in group B. Moreover, infants in treatment group 
C also experienced no benefit from normal bovine 
immunoglobulin concentrate. These findings strongly 
suggest that the mechanism of hyperimmune bovine 
immunoglobulin concentrate is a specific anti-diarrhea 
effect. 
Supplemented groups 
Nutritional indicator 
Group A 
(n=30) 
Group B 
(n=25) 
Group C 
(n=23) 
Control formula 
(n=29) 
Weight-for-age Z-score 0.85+0.08 0.25-tO.08, N’S 0.21kO.05, NS 0.5OkO.3 
Weight-for-length Z-score 0.21-c0.02 0.11 kO.01, NS 0.12-r-0.03, NS 0.10~0.02 
Length-for-age Z-score 0.41-to.07 0.15kO.08, NS 0.16kO.04, NS 0.13kO.02 
Weight reduction per day of diarrhea (g/day) 21.3-cl2.0 38.1k20.9, NS 41.4k20.5, NS 45.9218.9 
Weight reduction per episode of diarrhea (g) 95.8-cl7.3 228.9i29.8, NS 248.4e30.4. NS 298.4229.4 
aValues are means. NS, not significant. P~O.001, P~0.05. 
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Unlike infant formula, human breast milk varies 
greatly with respect to nutritional composition and 
other constituents, including contaminants and food 
antigens. In developing countries, the evidence for the 
protective effect of breastfeeding against diarrhea1 
diseases is fairly strong. 22 Exclusive breastfeeding is 
recommended worldwide as the optimal feeding method 
for young infants. 23,24 There is strong agreement as to its 
benefits in reducing diarrhea morbidity and mortality, 
especially in environments where sanitation is poor.25,26 
The economic sanctions on Iraq, which have 
continued since 1990, have added to the difficult situation 
that has prevailed due to the destruction of the country’s 
infrastructure, a reduced ability to treat sewage, and lack 
of medications and vaccines. This indirectly increased 
the incidence of waterborne diseases and severe gastro- 
enteritis.27 Moreover, UNICEF2* reported that, since 
December 1990, there has been a reduction in the 
breastfeeding of children less than 3 months of age, pro- 
bably due to nutritional and psychological stress. Recent 
studies have traced a steady decline in breastfeeding, 
exposing infants to greater risks of malnutrition30 and 
diarrhea (unpublished data). In this situation, the pro- 
motion of exclusive breastfeeding for the first 
4-6 months as a preventive measure against infant 
diarrhea acquires a special significance. 
The results of our study showed also that bovine 
colostral immunoglobulins from E. co&immunized 
cows reduced the number of enteropathogenic isolates 
that are present in the feces of infants. This effect was 
probably due to the specific anti-E. coli activities of these 
immunoglobulins. In a similar study, it was shown that 
administering a bovine milk immunoglobulin concentrate 
containing antibodies to EPEC to infected patients 
resulted in the elimination of these organisms from stool 
samples of 84.3% of the subjects.31 The present findings 
are particularly significant, since E. coli is the most 
common causal agent of diarrhea1 disease in Iraqi 
infants.5,32 A decrease in E. coli shedding may lead to 
less environmental exposure and thus may be beneficial 
in reducing the risk to surrounding infants of developing 
gastroenteritis. 
The observation that E. coli-specific immuno- 
globulins decreased the shedding of E. coli organisms 
suggests that the immunoglobulins interfered with 
replication and/or colonization.12 In mouse protection 
tests, the coating of bacteria with antibodies will inhibit 
bacterial adhesion to the mucosa and help phagocytosis 
by macrophages in the intestinal mucosa.13 It is not 
clear how well these assays measure protection against 
diarrhea in children.33 
Biological effects after the oral administration of 
immunoglobulins can be expected only if the immuno- 
globulins are significantly more resistant to total digestion 
by gastric enzymes than are normal dietary proteins. In 
infants given anti-E. coli CWP and in mouse protection 
tests, immunoelectrophoresis of stool extracts revealed 
unequivocally the passage of intact anti-E. co2i milk 
immunoglobulin. I6 In another series of experiments, 
orally administered immunoglobulins of human as well 
as bovine origin were detected in the feces of ill children 
and newborns,34 at rates more than 10% of those of the 
orally administered bovine immunoglobulins.31 Recently, 
it was shown that nearly 70% of the exogenous nitrogen 
recovered in the ileum originated from IgG of bovine 
origin, as confirmed by radial immunodiffusion.35 This is 
a further indication that immunoglobulin concentrates 
from bovine colostrum may have the potential to support 
the host defense system by passive immunization of the 
gut. 
The impact of diarrhea on infant growth and 
nutritional status is the outcome of a complex interplay 
of host, pathogen and sociocultural factors, which may 
cause decreased food intake, malabsorption, loss of 
endogenous nutrients, and increased metabolic rate.‘j A 
study in Nepal in children aged O-7 months found an 
average weight loss of 370 g during the month after the 
episode of diarrhea, compared with an average gain of 
110 g experienced by children who did not have diarrhea 
in the same month.36 Another study in Sudan in infants 
3-6 months old indicated that diarrhea produced a 
deficit in weight gain of 32 g/day of illness.37 
In the present study, the average loss in weight per 
day caused by diarrhea was higher in the control group 
than in group A, and the loss in weight associated with 
an episode of diarrhea in a given month was much 
greater than that in group A. The difference may be 
explained by the greater severity and duration of 
diarrhea reported for infants in the control group. 
Infants in treatment group A obtained benefit from 
passive protection against diarrhea through 6 months of 
follow-up. Thus, a supplement of hyperimmune immuno- 
globulin would maximize growth via minimization of 
diarrhea. 
A number of questions remain: 
1. The amount of the specific antibody necessary to 
provide protection against diarrhea caused by some 
EPEC strains in healthy infants of low economic 
status is unknown. Brunser et aP3 reported that 
feeding an antibody-supplemented infant formula 
containing 0.12 g/kg per day had no positive effect on 
diarrhea1 diseases. In the present study, feeding an 
antibody-supplemented infant formula containing 
0.5 g/kg per day had a positive effect. 
2. It is unknown whether it is necessary to immunize the 
donor animal. In a previous study in our laboratory, 
the chemical analysis of CWP preparations revealed 
statistically significant differences in the total protein 
and immunoglobulin contents of the colostrum of 
immunized and non-immunized cows. Similar results 
have been obtained by many workers.3s,39 By contrast, 
Stephan et a140 reported that the colostrum produced 
by a cow a few hours after calving has such a high 
immunoglobulin content that the immunization of 
the cow is unnecessary. 
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3. There may be a problem with the allergenicity of milk 
immunoglobulins. It is noteworthy that the supple- 
mented formula was well tolerated by all infants. 
4. It is unknown whether immunoglobulins can be 
economically extracted on a large scale. Production 
costs are difficult to evaluate. 
5. We produced immunoglobulin concentrates by 
immunizing cows with whole killed organisms. The 
antigenic specificities of the protective antibodies in 
these immunoglobulin concentrates are not known. 
Although we added a specific immunoglobulin concen- 
trate to infant formula, these immunoglobulins could be 
added to other foods suitable for ingestion by infants. 
Infants at high risk of enteropathogenic diarrhea could 
use these preparations, including those who cannot 
breastfeed and infants in nurseries. For this purpose, 
a product with antibodies against a broad spectrum of 
E. coli strains could be developed in a practical formu- 
lation designed to avoid use of local water, e.g. a wafer. 
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